-
1.发明授权Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates 失效用抗IL-8抗体片段 - 聚合物缀合物治疗炎性疾病的方法公开(公告)号：US06458355B1
公开(公告)日：2002-10-01
申请号：US09121952
申请日：1998-07-24
申请人： Vanessa Hsei , Iphigenia Koumenis , Steven Leong , Leonard Presta , Zahra Shahrokh , Gerardo Zapata
发明人： Vanessa Hsei , Iphigenia Koumenis , Steven Leong , Leonard Presta , Zahra Shahrokh , Gerardo Zapata
IPC分类号： A61K3944
CPC分类号： C07K16/244 , A61K47/60 , A61K2039/505 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2319/00 , Y10S530/866
摘要： Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate is at least about 500 kD.
摘要翻译： 本发明提供了一种治疗患者炎性疾病的方法，包括向患者施用有效量的基本上由一种或多种与一种或多种非蛋白质聚合物分子共价连接的抗体片段组成的缀合物，其中至少一种抗体片段包含抗原结合位点 其结合人IL-8，并且其中缀合物的表观尺寸为至少约500kD。
-
公开(公告)号：US20110104185A1
公开(公告)日：2011-05-05
申请号：US12850490
申请日：2010-08-04
IPC分类号： A61K39/395 , A61P1/00 , A61P29/00 , A61P19/02 , A61P11/00 , A61P25/00 , A61P17/00 , A61P11/06 , A61P31/04 , A61P9/00
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
摘要翻译： 描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子（VEGF），人p185受体样酪氨酸激酶（HER2），人CD20，人CD18，人CD11a，人IgE，人凋亡受体-2（Apo-2），人 肿瘤坏死因子-α（TNF-α），人组织因子（TF），人α4和bgr7整合素，人GPIIb-IIIa整合素，人表皮生长因子受体（EGFR），人CD3和人白细胞介素-2受体α- 链（TAC）用于诊断和治疗应用。
-
公开(公告)号：US07842789B2
公开(公告)日：2010-11-30
申请号：US12291750
申请日：2008-11-12
IPC分类号： C07K16/00
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
摘要翻译： 描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子（VEGF），人p185受体样酪氨酸激酶（HER2），人CD20，人CD18，人CD11a，人IgE，人凋亡受体-2（Apo-2），人 肿瘤坏死因子-α（TNF-α），人组织因子（TF），人α4和bgr7整合素，人GPIIb-IIIa整合素，人表皮生长因子受体（EGFR），人CD3和人白细胞介素-2受体α- 链（TAC）用于诊断和治疗应用。
-
公开(公告)号：US07507405B2
公开(公告)日：2009-03-24
申请号：US11541145
申请日：2006-09-28
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
-
5.发明申请Methods of binding TNF-alpha using Anti-TNF-alpha antibody fragment-polymer conjugates 有权使用抗TNF-α抗体片段 - 聚合物缀合物结合TNF-α的方法公开(公告)号：US20130084302A1
公开(公告)日：2013-04-04
申请号：US13372191
申请日：2012-02-13
IPC分类号： C07K17/02
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
摘要翻译： 描述了通过共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子（VEGF），人p185受体样酪氨酸激酶（HER2），人CD20，人CD18，人CD11a，人IgE，人凋亡受体-2（Apo-2），人 肿瘤坏死因子-α（TNF-α），人组织因子（TF），人α4和bgr7整合素，人GPIIb-IIIa整合素，人表皮生长因子受体（EGFR），人CD3和人白细胞介素-2受体α- 链（TAC）用于诊断和治疗应用。
-
公开(公告)号：US07214776B2
公开(公告)日：2007-05-08
申请号：US11259232
申请日：2005-10-25
IPC分类号： C07K16/00
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
摘要翻译： 描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子（VEGF），人p185受体样酪氨酸激酶（HER2），人CD20，人CD18，人CD11a，人IgE，人凋亡受体-2（Apo-2），人 肿瘤坏死因子-α（TNF-α），人组织因子（TF），人α4β7整联蛋白，人GPIIb-IIIa整联蛋白，人表皮生长因子受体（EGFR），人CD3和人白细胞介素-2受体α链 TAC）用于诊断和治疗应用。
-
公开(公告)号：US20060083683A1
公开(公告)日：2006-04-20
申请号：US11259232
申请日：2005-10-25
IPC分类号： A61K51/00 , A61K39/395 , C07K16/46
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
-
公开(公告)号：US07005504B2
公开(公告)日：2006-02-28
申请号：US09726258
申请日：2000-11-29
申请人： Vanessa Hsei , Iphigenia Koumenis , Steven Leong , Leonard Presta , Zahra Shahrokh , Gerardo Zapata
发明人： Vanessa Hsei , Iphigenia Koumenis , Steven Leong , Leonard Presta , Zahra Shahrokh , Gerardo Zapata
IPC分类号： C07K16/00
CPC分类号： C07K16/244 , A61K47/60 , A61K2039/505 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2319/00
摘要： Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
摘要翻译： 描述了用于诊断应用和治疗炎性疾病的人源化抗IL-8单克隆抗体及其变体。 还描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。
-
9.发明授权Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates 有权使用抗TNF-α抗体片段 - 聚合物缀合物结合TNF-α的方法公开(公告)号：US08652468B2
公开(公告)日：2014-02-18
申请号：US13372191
申请日：2012-02-13
IPC分类号： A61K39/395
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a nonproteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
摘要翻译： 描述了通过共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子（VEGF），人p185受体样酪氨酸激酶（HER2），人CD20，人CD18，人CD11a，人IgE，人凋亡受体-2（Apo-2），人 肿瘤坏死因子-α（TNF-α），人组织因子（TF），人α4β7整联蛋白，人GPIIb-IIIa整联蛋白，人表皮生长因子受体（EGFR），人CD3和人白细胞介素-2受体α链 TAC）用于诊断和治疗应用。
-
公开(公告)号：US08147830B2
公开(公告)日：2012-04-03
申请号：US12850490
申请日：2010-08-04
IPC分类号： A61K39/395
CPC分类号： C07K17/02 , A61K39/3955 , A61K47/60 , A61K47/6845 , A61K2039/505 , C07K16/22 , C07K16/244 , C07K2317/24 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
摘要翻译： 描述了由共价连接到非蛋白质聚合物上的抗体片段形成的缀合物，其中缀合物的表观尺寸为至少约500kD。 与未衍生的亲本抗体片段相比，缀合物显示出显着改善的循环中的半衰期，平均停留时间和/或清除率。 还描述了针对人血管内皮生长因子（VEGF），人p185受体样酪氨酸激酶（HER2），人CD20，人CD18，人CD11a，人IgE，人凋亡受体-2（Apo-2），人 肿瘤坏死因子-α（TNF-α），人组织因子（TF），人α4和bgr7整合素，人GPIIb-IIIa整合素，人表皮生长因子受体（EGFR），人CD3和人白细胞介素-2受体α- 链（TAC）用于诊断和治疗应用。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.058 秒)
